Suppr超能文献

欧洲耐多药结核病的危险因素:一项系统综述

Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

作者信息

Faustini A, Hall A J, Perucci C A

机构信息

Department of Epidemiology, RME, 00198 Rome, Italy.

出版信息

Thorax. 2006 Feb;61(2):158-63. doi: 10.1136/thx.2005.045963. Epub 2005 Oct 27.

Abstract

BACKGROUND

The resurgence of tuberculosis (TB) in western countries has been attributed to the HIV epidemic, immigration, and drug resistance. Multidrug resistant tuberculosis (MDR-TB) is caused by the transmission of multidrug resistant Mycobacterium tuberculosis strains in new cases, or by the selection of single drug resistant strains induced by previous treatment. The aim of this report is to determine risk factors for MDR-TB in Europe.

METHODS

A systematic review was conducted of published reports of risk factors associated with MDR-TB in Europe. Meta-analysis, meta-regression, and sub-grouping were used to pool risk estimates of MDR-TB and to analyse associations with age, sex, immigrant status, HIV status, occurrence year, study design, and area of Europe.

RESULTS

Twenty nine papers were eligible for the review from 123 identified in the search. The pooled risk of MDR-TB was 10.23 times higher in previously treated than in never treated cases, with wide heterogeneity between studies. Study design and geographical area were associated with MDR-TB risk estimates in previously treated patients; the risk estimates were higher in cohort studies carried out in western Europe (RR 12.63; 95% CI 8.20 to 19.45) than in eastern Europe (RR 8.53; 95% CI 6.57 to 11.06). National estimates were possible for six countries. MDR-TB cases were more likely to be foreign born (odds ratio (OR) 2.46; 95% CI 1.86 to 3.24), younger than 65 years (OR 2.53; 95% CI 1.74 to 4.83), male (OR 1.38; 95% CI 1.16 to 1.65), and HIV positive (OR 3.52; 95% CI 2.48 to 5.01).

CONCLUSIONS

Previous treatment was the strongest determinant of MDR-TB in Europe. Detailed study of the reasons for inadequate treatment could improve control strategies. The risk of MDR-TB in foreign born people needs to be re-evaluated, taking into account any previous treatment.

摘要

背景

西方国家结核病(TB)的再度流行归因于艾滋病病毒(HIV)流行、移民和耐药性。耐多药结核病(MDR-TB)是由新病例中耐多药结核分枝杆菌菌株的传播引起的,或者是由先前治疗诱导的单耐药菌株的选择导致的。本报告的目的是确定欧洲耐多药结核病的危险因素。

方法

对欧洲与耐多药结核病相关的危险因素的已发表报告进行系统综述。采用荟萃分析、荟萃回归和亚组分析来汇总耐多药结核病的风险估计值,并分析其与年龄、性别、移民身份、HIV状态、发生年份、研究设计和欧洲地区的关联。

结果

在检索到的123篇文献中,有29篇符合综述要求。既往接受过治疗的患者中耐多药结核病的汇总风险比从未接受过治疗的患者高10.23倍,研究之间存在广泛的异质性。研究设计和地理区域与既往接受过治疗的患者的耐多药结核病风险估计值相关;在西欧进行的队列研究中的风险估计值(相对危险度(RR)12.63;95%置信区间(CI)8.20至19.45)高于东欧(RR 8.53;95% CI 6.57至11.06)。六个国家能够得出全国性估计值。耐多药结核病病例更可能是外国出生(优势比(OR)2.46;95% CI 1.86至3.24)、年龄小于65岁(OR 2.53;95% CI 1.74至4.83)、男性(OR 1.38;95% CI 1.16至1.65)以及HIV阳性(OR 3.52;95% CI 2.48至5.01)。

结论

既往治疗是欧洲耐多药结核病的最强决定因素。对治疗不充分的原因进行详细研究可能会改善控制策略。考虑到任何既往治疗情况,需要重新评估外国出生人群中耐多药结核病的风险。

相似文献

1
Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.
Thorax. 2006 Feb;61(2):158-63. doi: 10.1136/thx.2005.045963. Epub 2005 Oct 27.
2
4
Tuberculosis treatment outcomes in Europe: a systematic review.
Eur Respir J. 2005 Sep;26(3):503-10. doi: 10.1183/09031936.05.00103504.
5
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.
Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2.
6
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
7
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Sertindole for schizophrenia.
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
9
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
10
Selenium for preventing cancer.
Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4.

引用本文的文献

1
Drug resistance among students with pulmonary tuberculosis: a study based on screening in Henan, China.
BMC Infect Dis. 2025 Aug 8;25(1):1002. doi: 10.1186/s12879-025-11408-1.
4
Prevalence and molecular characterization of drug-resistant in Heyuan City in China.
Front Cell Infect Microbiol. 2025 Jun 12;15:1586938. doi: 10.3389/fcimb.2025.1586938. eCollection 2025.
5
Resistance Rates of Complex Strains: A Retrospective Study in Türkiye.
Medicina (Kaunas). 2025 Jun 9;61(6):1060. doi: 10.3390/medicina61061060.
6
Spatiotemporal analysis of tuberculosis drug resistance and associated risk factors in Tanzania.
Ther Adv Infect Dis. 2025 Jun 1;12:20499361251339576. doi: 10.1177/20499361251339576. eCollection 2025 Jan-Dec.
8
Risk factors for multidrug resistance in pulmonary tuberculosis patients with diabetes mellitus.
Front Med (Lausanne). 2025 Jan 31;12:1516207. doi: 10.3389/fmed.2025.1516207. eCollection 2025.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验